Merkel cell carcinoma (MCC) is rare. Roughly 3,000 to 3,300 new cases are diagnosed each year in the United States, making it about 35 times less common than melanoma. For context, melanoma affects roughly 100,000 Americans annually, while MCC affects a small fraction of that. Despite its rarity, MCC has been rising faster than nearly any other solid tumor, and it carries a higher recurrence rate than most skin cancers.
How the Numbers Compare to Other Skin Cancers
The age-adjusted incidence of MCC is approximately 5.9 per million people, compared to about 204 per million for cutaneous melanoma. That means MCC is roughly 32 times less common than melanoma in men and 38 times less common in women. Basal cell carcinoma and squamous cell carcinoma, the two most common skin cancers, are each diagnosed in the millions every year, putting MCC in an entirely different category of rarity.
That rarity can be misleading, though. MCC is more aggressive than most skin cancers, and because few people have heard of it, diagnoses often come late. Its five-year recurrence rate is around 40%, far higher than melanoma (about 19%), squamous cell carcinoma (5% to 9%), or basal cell carcinoma (1% to 2%).
Cases Are Rising Fast
Between 2000 and 2013, reported MCC cases in the U.S. nearly doubled, a 95% increase. During that same period, melanoma cases rose 57% and all solid cancers combined rose just 15%. The primary driver is an aging population. MCC risk climbs sharply with age, and as the baby-boom generation moves into their 70s and 80s, the pool of high-risk individuals keeps expanding. Researchers projected roughly 2,835 cases in 2020 and 3,284 in 2025, a trajectory that appears to be on track.
Better awareness and improved diagnostic tools also play a role. Pathologists now have more reliable ways to identify MCC under the microscope, which means some cases that would have been misclassified in earlier decades are now being counted.
Who Gets MCC
MCC overwhelmingly affects older, fair-skinned individuals. The vast majority of cases occur in non-Hispanic White patients, who have an incidence rate of about 0.8 per 100,000. Hispanic patients have a rate of roughly 0.3, and Black patients about 0.1. Men are diagnosed more often than women.
Geography matters too. Incidence is highest in Australia, New Zealand, the United States, and Israel among men. Among women, New Zealand, Australia, Ireland, and the Netherlands top the list. These patterns track closely with UV exposure and the proportion of fair-skinned populations in each country.
The Role of a Common Virus
About 80% of MCC tumors contain a virus called Merkel cell polyomavirus. Most people are exposed to this virus at some point in their lives without ever developing cancer. In rare cases, the virus integrates into skin cell DNA in a way that drives uncontrolled growth. The remaining 20% or so of MCC cases are virus-negative and tend to show heavy UV damage signatures in their DNA instead, suggesting chronic sun exposure as the main trigger.
Immunosuppression Multiplies the Risk
A weakened immune system is one of the strongest known risk factors for MCC. Organ transplant recipients face a 13-fold higher risk compared to the general population. People with AIDS historically had a similarly elevated risk, around 13 times higher, though more recent data with modern HIV treatment estimates the risk closer to 3 times higher. Certain blood cancers also raise vulnerability: people with chronic lymphocytic leukemia have nearly 6 times the expected risk of developing MCC.
This connection makes sense given the viral link. A healthy immune system typically keeps Merkel cell polyomavirus in check. When immune surveillance weakens, the virus has more opportunity to cause trouble.
Survival Depends Heavily on Stage
When MCC is caught early and confined to the skin, outcomes are very good. Patients with stage I disease have a 95% cancer-specific survival rate at five years. Once the cancer has spread to distant sites (stage IV), that number drops to 41%. This wide gap underscores why early detection matters so much for a cancer this aggressive.
More than 90% of MCC recurrences happen within the first three years after treatment, which is why follow-up visits are typically more frequent during that window and taper off afterward. The 40% overall recurrence rate means ongoing monitoring is a significant part of life after an MCC diagnosis, even for patients whose initial treatment goes well.
Why a Rare Cancer Still Matters
With roughly 3,000 to 3,300 new U.S. cases per year, MCC will never be a household name the way melanoma is. But its rapid growth rate, high recurrence risk, and strong connection to immune health make it disproportionately important in dermatology and oncology. If you’re over 65, have fair skin, a history of heavy sun exposure, or a compromised immune system, MCC is worth knowing about, even if the odds of any single person developing it remain very low.